Nurix Therapeutics, Inc. SEC Filings

Nurix Therapeutics, Inc.’s Chief Financial Officer, Hans van Houte, reported routine equity compensation activity and related tax sales. On January 30, 2026, several blocks of restricted stock units (RSUs) converted into common stock at $0 exercise price, including 2,887, 2,000, 3,750 and 2,859 RSUs.

To cover tax withholding from these RSU vestings, the CFO sold 3,588 shares at a weighted average price of $16.5826 and 73 shares at a weighted average price of $17.3717. The filing states these are mandatory “sell to cover” transactions, not discretionary trades. After the transactions, he directly owned 45,427 common shares and 25,725 RSUs.

Nurix Therapeutics Chief Legal Officer Christine Ring reported RSU vesting and related share sales. On January 30, 2026, multiple blocks of restricted stock units were converted into common stock at an exercise price of $0, increasing her directly held common shares.

On the same date, she sold 4,333 and 88 common shares at weighted average prices of $16.5826 and $17.3717, respectively. A footnote explains these sales were mandated "sell to cover" transactions to satisfy tax withholding on RSU vesting, not discretionary trades. After these transactions, she directly owned 57,010 common shares and held 25,725 RSUs.

Nurix Therapeutics Chief Scientific Officer Gwenn Hansen reported RSU vesting and related tax-share sales. On January 30, 2026, RSUs covering 3,207, 2,000, 3,750, and 2,859 shares were converted into common stock at $0 per share.

To cover tax withholding from these RSU vestings, Hansen sold 4,797 and 98 common shares in mandated “sell to cover” transactions at weighted average prices of $16.5826 and $17.3717. After these trades, Hansen directly beneficially owned 83,672 common shares and held 25,725 RSUs.

Nurix Therapeutics details in its annual report a broad clinical and partnering strategy built around targeted protein degradation for cancer and inflammatory diseases. The company’s wholly owned pipeline includes three clinical candidates: BTK degraders bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127), and CBL‑B inhibitor NX‑1607.

Bexobrutideg is in a potentially pivotal Phase 2 study for heavily pretreated CLL/SLL and has U.S. Fast Track and EU PRIME designations, with additional data in Waldenström macroglobulinemia. NX‑1607 shows early immune‑oncology activity across solid tumors. Nurix also highlights its DEL‑AI discovery platform, DAC technology and collaborations with Gilead, Sanofi and Pfizer, which have provided $482 million in non‑dilutive funding and could yield up to $6.1 billion in future milestones.

Nurix Therapeutics, Inc. filed a current report to note that on January 28, 2026 it issued a press release announcing its financial results for the fiscal quarter and year ended November 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference.

The company clarifies that the information provided under Item 2.02, including Exhibit 99.1, is furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.

Nurix Therapeutics, Inc. insider activity: Chief Legal Officer Christine Ring reported option exercises and share sales in Nurix Therapeutics, Inc. common stock. On 01/20/2026, she exercised 3,760 employee stock options at an exercise price of $1.86 per share, acquiring 3,760 shares of common stock. That same day, she sold 3,760 shares of common stock at a weighted average price of $18.4237 per share under a previously adopted Rule 10b5-1 trading plan. After these transactions, she beneficially owned 50,897 shares of common stock directly and 8,643 stock options.

Nurix Therapeutics, Inc. filed a current report to share that it is presenting at the 44th Annual J.P. Morgan Healthcare Conference. On January 12, 2026, the company is providing an overview of its 2025 performance and outlining major goals for 2026 at the event. The associated investor presentation is included as Exhibit 99.1, and a related press release is included as Exhibit 99.2.

The company notes that this conference information is being furnished under Regulation FD and is not deemed filed for liability purposes under the Securities Exchange Act. The filing is primarily informational and centers on disclosure of the materials used at the conference and the accompanying press release.

Nurix Therapeutics, Inc. insider transaction: The company’s Chief Legal Officer, identified as the reporting person, exercised an employee stock option to acquire 3,760 shares of Nurix common stock at an exercise price of $1.86 per share on 12/18/2025. The same day, the insider sold 3,560 shares of common stock at a weighted average price of $17.8661 per share and an additional 200 shares at a weighted average price of $18.555 per share.

These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. After these transactions, the reporting person beneficially owned 50,897 shares of Nurix common stock directly and held 12,403 employee stock options. The option exercised on this date had fully vested by August 9, 2023.

Nurix Therapeutics, Inc. reported an insider equity transaction by its Chief Legal Officer, Christine Ring. On 11/24/2025, she exercised an employee stock option to acquire 37,600 shares of common stock at an exercise price of $1.86 per share, then sold 37,600 shares of common stock on the same date at a weighted average price of $17.0664 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she beneficially owned 50,897 shares of Nurix common stock directly and 16,163 employee stock options.